EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Compassionate treatment with a monoclonal antibody-purified factor IX concentrate in hemophilia B surgical patients who have experienced thrombotic complications with prothrombin complex concentrates



Compassionate treatment with a monoclonal antibody-purified factor IX concentrate in hemophilia B surgical patients who have experienced thrombotic complications with prothrombin complex concentrates



Blood 82(10 SUPPL 1): 154A




(PDF emailed within 1 workday: $29.90)

Accession: 030653090

Download citation: RISBibTeXText



Related references

Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 79(3): 568-575, 1992

Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate. Seminars in Hematology 28(3 Suppl 6): 15-19, 1991

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thrombosis & Haemostasis 73(5): 779-784, 1995

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thrombosis and Haemostasis 75(1): 30-35, 1996

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. Thrombosis and Haemostasis 73(5): 779-784, 1995

Safety and efficacy of monoclonal antibody purified factor IX concentrate for management of spontaneous or trauma-induced bleeding and surgical prophylaxis in children with hemophilia B. Pediatric Research 35(4 PART 2): 163A, 1994

Treatment by continuous infusion with Monoclonal Antibody Purified factor IX in hemophilia B patients in surgical, trauma, or severe spontaneous hemorrhage. Blood 98(11 Part 1): 532a, November 16, 2001

Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion 30(5): 441-443, 1990

Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Haemophilia 3(4): 247-253, 1997

Lack of immune response to mouse IgG in previously untreated hemophilia A and hemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations. Blood 86(10 SUPPL 1): 868A, 1995

Half-life, recovery and efficacy of continuous infusion monoclonal antibody purified factor IX in hemophilia B surgical, trauma, or severe spontaneous hemorrhage patients. Blood 90(10 SUPPL 1 PART 1): 35A, Nov 15, 1997

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial. Thrombosis Journal 16: 1-1, 2018

A survey of the effectiveness of prothrombin complex concentrates in controlling hemorrhage in patients with hemophilia and anti-Factor VIII antibodies. Thrombosis and Haemostasis 44(1): 39-42, 1980

Combination Therapy with Activated Prothrombin Complex Concentrate and Recombinant Factor VIIa in Patients with Severe Hemophilia and Inhibitors. Blood 100(11): Abstract No 2742, November 16, 2002

A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. British Journal Of Haematology. 87(4): 782-788, 1994